Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation (Nasdaq: IART) is frequently featured in healthcare and capital markets news as a global medical technology company focused on neurosurgery, tissue reconstruction, and regenerative care. Its news flow, as reflected in recent press releases, spans financial results, regulatory milestones, clinical technology updates, policy developments, and investor conference participation.
Investors following IART news will see regular quarterly earnings announcements, typically accompanied by detailed segment commentary for Codman Specialty Surgical and Tissue Technologies, as well as discussions of organic revenue trends, adjusted profitability metrics, and management’s outlook. These releases are often paired with notices of conference calls and webcasts accessible through the company’s investor relations channels.
Beyond financial reporting, Integra issues news on regulatory and clinical developments. Recent examples include FDA 510(k) clearance for expanded use of the CUSA Clarity Ultrasonic Surgical Aspirator System in cardiac surgery and updates on neurosurgical technologies such as CereLink, Aurora, Mayfield devices, and Durepair Dura Regeneration Matrix. The company also highlights its presence at major clinical meetings, including the Congress of Neurological Surgeons Annual Meeting, where it showcases its neurosurgical portfolio.
Policy and reimbursement developments are another theme in Integra’s news. The company has commented on CMS rules affecting Medicare beneficiary access to skin substitutes, noting the inclusion of its dermal regenerative templates, decellularized dermal scaffolds, and amniotic tissue membranes, as well as specific brands like Integra matrices, PriMatrix, Cytal, and AmnioExcel.
In addition, IART news covers leadership and governance updates, such as the appointment of a chief medical officer and participation by senior executives in investor healthcare conferences. For readers and investors, the IART news page offers a centralized view of Integra’s financial performance, product and regulatory milestones, policy environment, and corporate developments.
Integra LifeSciences Holdings (NASDAQ: IART), a leading global medical technology company, has announced it will release its second quarter 2024 financial results on Monday, July 29, 2024, before the market opens. The company's management team will host a conference call at 8:30 a.m. ET on the same day to discuss the results.
A live webcast of the conference call will be available on the Investors section of Integra's website at investor.integralife.com. Interested participants can register to receive dial-in details and an individual pin for the call. Integra recommends joining the call 10 minutes before it starts. A webcast replay will be available on the company's Investors section following the call.
Integra LifeSciences Holdings (NASDAQ: IART), a prominent medical technology company, announced that its CFO, Lea Knight, will present at the 2024 Bank of America Healthcare Conference on May 14, 2024, at 4:40pm ET. The presentation will be livestreamed on the company's investor relations website.
Integra LifeSciences Holdings reported first quarter 2024 financial results, with revenues of $368.9 million declining 3.1% on a reported basis and 2.5% on an organic basis compared to the prior year. GAAP earnings per share were $(0.04), while adjusted earnings per share were $0.55. The company completed the acquisition of Acclarent, Inc., updating full-year revenue guidance to a range of $1.672 billion to $1.687 billion.
Integra LifeSciences will showcase the CereLink® Intracranial Pressure (ICP) Monitoring System at the AANS Annual Scientific Meeting. The system offers advanced continuous ICP monitoring with minimal drift, MR conditional capability, durable sensors, and advanced data features. The relaunch addresses the important need for accurate ICP monitoring in managing brain injuries, strokes, and other conditions, demonstrating Integra's commitment to innovation and patient care.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.